Eikon Therapeutics

EIKN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Value held

$466k

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$13.05

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

0Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Eikon Therapeutics.

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Eikon Therapeutics

Polen Capital Management	0.0%$466k	$466k	New	1 qtr

Download the holders: CSV · JSON · Markdown

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Eikon Therapeutics
		Bought or sold				Filing
3 Sep 2026	Column Group IV Gp, LP10% owner	▲ Bought	89,200	$11.56	$1.0m	Form 4